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A B S T R A C T
Background and purpose: Accurate quantiﬁcation of the relatively small radiation doses delivered to untargeted
regions during breast irradiation in patients with breast cancer is of increasing clinical interest for the purpose of
estimating long-term radiation-related risks. Out-of-ﬁeld dose calculations from commercial planning systems
however may be inaccurate which can impact estimates for long-term risks associated with treatment. This work
compares calculated and measured dose out-of-ﬁeld and explores the application of a correction for leakage
radiation.
Materials and methods: Dose calculations of a Boltzmann transport equation solver, pencil beam-type, and su-
perposition-type algorithms from a commercial treatment planning system (TPS) were compared with in vivo
thermoluminescent dosimetry (TLD) measurements conducted out-of-ﬁeld on the contralateral chest at points
corresponding to the thyroid, axilla and contralateral breast of eleven patients undergoing tangential beam
radiotherapy for breast cancer.
Results: Overall, the TPS was found to under-estimate doses at points distal to the radiation ﬁeld edge with a
modern linear Boltzmann transport equation solver providing the best estimates. Application of an additive
correction for leakage (0.04% of central axis dose) improved correlation between the measured and calculated
doses at points greater than 15 cm from the ﬁeld edge.
Conclusions: Application of a correction for leakage doses within peripheral regions is feasible and could im-
prove accuracy of TPS in estimating out-of-ﬁeld doses in breast radiotherapy.
1. Introduction
With a signiﬁcant reduction in recurrence rates and breast cancer
mortality compared with surgery alone [1,2] whole breast irradiation
following breast conserving surgery is standard practice for patients
with early stage breast cancer. However, there is concern that in-
cidental out-of-ﬁeld radiation doses to the untargeted normal tissues
during breast radiotherapy may be associated with an increased risk of
secondary malignancy [3–7]. The improving survival of patients with
early breast cancer underpins this concern, and adds emphasis to the
need to accurately quantify radiation doses to untargeted healthy tis-
sues during treatment for a more accurate estimation of the risk of
radiation-related second malignancy. In addition, the out-of-ﬁeld ra-
diation received by surrounding healthy tissues during breast irradia-
tion is associated with toxicities of the heart, lung and thyroid [8–10].
Risk of ischemic heart disease in patients following radiotherapy for left
sided breast cancer has been shown to be dose dependent [8]. The
geometry of tangential beam radiotherapy in particular raises questions
regarding the dose delivered to the contralateral breast. This is parti-
cularly important as the breast tissue is assigned a relatively high
weighting factor for radiation protection purposes, reﬂecting its sensi-
tivity to radiation [11]. The risk of radiation-related contralateral
breast cancer following ipsilateral breast radiotherapy is thought to be
dose-dependent [12,13]. Any reduction in out-of-ﬁeld dose to healthy
tissue is therefore important for long term risk reduction, and accurate
calculation of out-of-ﬁeld dose to the contralateral breast is crucial for
informing risk estimates.
The out-of-ﬁeld dose results from leakage radiation from the linear
accelerator scatter from the collimators and beam modiﬁers, and in-
patient scatter. The latter contribution is accounted for by the treatment
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planning system (TPS) at regions relatively close to the beam. However,
linear accelerator-speciﬁc contribution to out-of-ﬁeld dose is largely
unaccounted for by dose calculation algorithms since head leakage
contributions are usually not explicitly considered during beam data
acquisition at commissioning of a new TPS. Thus, radiation dose from
machine leakage and head scatter is not accounted for at peripheral
regions during treatment planning. These are also the dominant con-
tributors to out-of-ﬁeld dose at distances greater than approximately
30 cm from the beam edge depending on treatment parameters [14]
corresponding to regions of untargeted healthy tissue. Others have
shown that neutron contamination also begins to contribute to out-of-
ﬁeld dose in higher energy treatments above approximately 10MV
[15,16], which is also not explicitly modelled.
Previous work has provided systematic analysis of out-of-ﬁeld dose
proﬁles under various treatment parameters in a phantom. Howell et al.
reported a commercial system to have underestimated out-of-ﬁeld dose
by an average of 40% between 3.75 and 11.25 cm from the ﬁeld edge
[17], with the magnitude of this discrepancy increasing at larger dis-
tances. Huang et al. analysed the out-of-ﬁeld dose for IMRT treatments
and similarly concluded the TPS underestimated out-of-ﬁeld dose, in
this case by an average of 50% [18]. The recent AAPM TG 158 pub-
lication [19] discussed the challenges associated with quantifying out-
of-ﬁeld dose in modern radiotherapy, highlighting the importance of
extra target doses as a consideration for long term patient outcomes and
providing physicists and clinicians with guidance for assessing such
doses. A comprehensive review of out-of-ﬁeld dose and risk estimates in
radiotherapy is also provided by Xu et al. [20].
Previous groups have analysed the out-of-ﬁeld dose from diﬀerent
TPS algorithms in water phantoms [21,22], with others using anthro-
pomorphic phantoms to better represent patient treatment [17,23].
Such phantom studies allow treatment parameters to be systematically
altered to study their individual eﬀects on the out-of-ﬁeld dose, and in
turn the ability of the TPS to model these eﬀects. Johansen et al. [24]
measured higher contralateral breast dose with inclusion of a supra-
clavicular fossa ﬁeld in regional nodal irradiation following TLD mea-
surements, concluding that a collapsed cone algorithm was better able
to estimate the out-of-ﬁeld dose compared to a pencil beam algorithm.
Saur et al. used GafChromic ECT ﬁlm in a phantom to assess con-
tralateral breast dose from diﬀerent planning techniques, demon-
strating higher contralateral breast dose from hard wedges compared to
virtual wedges and concluding the TPS algorithms were inadequate for
modelling these doses [25]. Joosten et al. [26] performed Monte Carlo
simulations on patient CT scans to compare out-of-ﬁeld dose from IMRT
and conventional tangent breast irradiation techniques. They found
that out-of-ﬁeld head scatter, which is not adequately modelled by the
TPS, contributed a large portion of the out-of-ﬁeld dose. Similarly to
phantom studies, the TPS was found to under-estimate dose to healthy
tissues beyond the treatment beams. Monte Carlo is the ‘gold standard’
for calculating dose deposition in various media and provides the op-
portunity to compare out-of-ﬁeld dose from diﬀerent planning techni-
ques on a patient CT scan – which cannot be done via in vivo dosimetry
– however, with the peripheral dose shown to vary among diﬀerent
accelerator designs [27], direct measurement is still required to accu-
rately assess patient doses from a given radiotherapy treatment.
In vivo dosimetry at peripheral locations during radiotherapy is not
common practice. As a result, dose calculations by the TPS are usually
the only indication of the dose to peripheral tissues such as the con-
tralateral breast. Thus, the aim of the current study was to assess the
accuracy of dose calculations at peripheral locations using diﬀerent
algorithms from a commercial treatment planning system by comparing
the calculated doses with in vivo thermoluminescent dosimeter (TLD)
measurements conducted out-of-ﬁeld on the contralateral chest of
eleven patients undergoing breast radiotherapy. In addition, the current
study aimed to improve the TPS calculation accuracy with the appli-
cation of a correction for leakage dose.
2. Materials and methods
2.1. Patient cohort
In vivo thermoluminescent dosimetry (TLD) measurements were
performed in eleven patients who underwent ipsilateral whole breast
irradiation following breast conserving surgery for early breast cancer
(Table 1, Supplementary material). All patients provided informed
consent for this study which was approved by the Human Research
Ethics Committee of the Peter MacCallum Cancer Centre in Melbourne,
Australia.
2.2. Treatment planning system calculations
A tangential photon beam treatment plan was created on the
planning CT scan for each patient as per institutional practice. The la-
terality of the treated site, use of a ﬁeld-in-ﬁeld technique, gantry angle,
dynamic wedge angle, ﬁeld size, and number of monitor units used for
each patient are summarised in Table 1 (Supplementary material). Each
patient underwent treatment as planned. The dose at each pre-speciﬁed
measurement point (Fig. 1a) was re-calculated in the TPS software
(Eclipse version 13.6, Varian Medical Systems, Palo Alto, CA) using the
convolution-based Analytical Anisotropic Algorithm (AAA, referred to
as “convolution” herein), Pencil Beam Convolution (PBC, referred to as
“pencil beam” herein), and a more modern linear Boltzmann transport
equation solver Acuros XB (referred to as “Boltzmann solver” herein). A
1.0 cm thick layer of bolus was added to each patient CT dataset to
simulate buildup conditions provided by the TLD perspex holders,
Fig. 1. (a) Diagram depicting measurement Points A, B, C and D on the contralateral breast (3 cm from the nipple in four cardinal directions); Point E at the contralateral mid axilla; and
Point F at the suprasternal notch, and (b) diagram depicting build-up domes used for in vivo measurements, adapted from Lonski et al. 2014 [30].
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which were not applied during the planning CT scan. The dose to each
measurement point was recorded for each algorithm and compared to
the measured dose acquired in vivo.
2.3. In vivo measurements
Measurements were performed using high sensitivity TLD chips
which were placed inside custom-made perspex ‘build-up domes’. The
domes (Fig. 1b) were designed to provide 1 cm build-up material with
minimal directional dependence. LiF:Mg,Cu,P, or “TLD-100H”, chips
(Harshaw, Kansas, USA) were selected for their high sensitivity and
near-tissue radiological equivalence, making them a suitable dosimeter
for in vivo measurements at peripheral locations [28]. Three TLD chips
were used at each measurement location. The chips were calibrated
prior to use in a 6MV photon beam using solid water slabs and each
chip was assigned an individual sensitivity factor according to its in-
dividual response to the batch average following irradiation. TLD chips
were read out using a Harshaw 5500 automatic TLD reader. For TLD-
100H, the combined use of multiple chips for each measurement and a
careful calibration process with tightly controlled handling and readout
process yields an overall measurement uncertainty of± 2% at the 95%
conﬁdence level for each measurement [29]. For in vivo dosimetry,
positioning of the buildup domes and dose gradients across the dome
area increases the measurement uncertainties, estimated here to be
10% (Type B).
All patients were treated on a Varian 21-X medical linear accel-
erator. In vivo measurements were conducted at six pre-deﬁned points
peripheral to the treated region which were nominally identical on all
patients: four on the contralateral breast, one at the contralateral mid
axilla and one at the suprasternal notch, indicating dose to the thyroid
gland (Fig. 1a). Three TLD chips were placed inside each buildup dome
and a single dome was taped to the patients’ skin at each point. Mea-
surements were taken for a single fraction and results extrapolated for a
complete 25-fraction treatment. All patients were treated on a Varian
21-iX medical linear accelerator using 6 MV (TPR20,10= 0.668) photon
beams.
Based on the TLD measurement locations (Fig. 1a), there were three
distinct regions deﬁned as a function of distance from the most prox-
imal edge of the largest ﬁeld (0–5 cm, denoted region 1; 10–15 cm,
denoted region 2; and>15 cm, denoted region 3 herein). Points B and
F were located in region 1, Points C and D were located in region 2, and
Points A and E were located in region 3 (with a maximum distance of
24 cm from the ﬁeld edge).
2.4. Analysis
TLD data was compared to TPS point dose calculations at Points A to
F (Fig. 1a). Discrepancies between the planned and measured doses
were evaluated as a function of distance from the most proximal ra-
diation ﬁeld edge.
2.5. Leakage dose correction
Discrepancies at locations distal to the primary radiation ﬁeld were
assumed to be due to machine leakage radiation. The use of a single-
value correction factor for leakage radiation was assessed to determine
if it improved accuracy of TPS in estimating doses at peripheral sites
where TPS calculations did not explicitly account for leakage con-
tributions. Measured doses which were less than 1 Gy total over the 25
fraction treatment were considered for this leakage correction. The
leakage component was assumed to be additive. The corrected dose,
Dcorr, in Gy, may be expressed as:
= + ×D (Gy) D (Gy) (C 50 Gy prescribed dose)corr calc leak (1)
where Dcalc is the uncorrected calculated TPS dose; and Cleak is the
correction for leakage dose expressed as a percentage of a 50 Gy pre-
scription. The optimal Cleak value was determined mathematically by
considering the discrepancies at each point between measured dose and
calculated dose for the cohort of eleven patients.
For in vivo data, the sensitivity-corrected thermoluminescence signal
was expressed as measured dose (Gy) calibrated against standard TLDs
irradiated to a known dose delivered under standard conditions using a
6MV 10×10 cm2 ﬁeld at the depth of maximum build-up with the
provision of suﬃcient backscatter material. The measured dose for a
single fraction was extrapolated to a measured dose for the entire
treatment course and was accordingly expressed in the following sec-
tions.
3. Results
3.1. TPS accuracy
Measured and calculated doses decreased approximately ex-
ponentially as a function of distance from the ﬁeld edge at peripheral
regions as is shown in Fig. 2a. However, TLD doses decreased less ra-
pidly with distance than the TPS calculated doses in regions beyond
20 cm from the ﬁeld edge. The correlation between calculated and
measured data is shown in Fig. 2b. The ratios of TPS calculated dose:
TLD measured dose are shown as a function of distance from the ﬁeld
Fig. 2. (a) Doses from TPS calculations and TLD measurements as a function of distance from the ﬁeld edge at out-of-ﬁeld regions for eleven breast cancer patients treated with ipsilateral
whole breast radiotherapy; and (b) ratios of TPS calculated dose: TLD measured dose as a function of distance from the ﬁeld edge.
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edge. The Boltzmann solver was shown to be the most accurate algo-
rithm in general across all regions but it under-estimated the measured
dose in region 3.
The average ratios of calculated dose: measured dose in region 1
were 0.84, 1.31 and 1.12 for the convolution-based algorithm, pencil
beam type algorithm and Boltzmann solver, respectively. In region 2,
these ratios were 0.27, 1.32 and 1.01, respectively. In region 3, the
convolution algorithm did not provide an estimate of the dose. The
ratios were 0.74 for the pencil beam and 0.48 for the Boltzmann solver.
The spread of the data can be seen in Fig. 2b.
3.2. Consideration of leakage radiation
The value at which TPS-calculated and TLD-measured dose diﬀer-
ences was at a minimum for all dose points less than 1 Gy was taken as
the leakage correction. Discrepancies between the TPS-calculated and
TLD-measured doses reduced to a minimum for all patients when an
additive leakage correction of 0.04% was applied to the Boltzmann
solver out-of-ﬁeld calculation dose as per Equation 1. A single value
leakage correction was not able to improve the out-of-ﬁeld dose cal-
culations for the convolution based or pencil beam type algorithms.
Without a leakage correction, the Boltzmann solver was found to be the
most accurate algorithm (Fig. 2b). The correlation between the Boltz-
mann solver calculated doses and TLD measured doses before and after
application of leakage correction is shown in Fig. 3.
The addition of a 0.04% leakage correction to the Boltzmann solver
data improved the average ratio of TPS-calculated dose: TLD-measured
dose for this patient cohort in region 3. The correction did not improve
dose calculations in regions closer to the radiation ﬁelds. The average
ratios of TPS-calculated dose: TLD-measured dose for the Boltzmann
solver were 1.12 in region 1, 1.01 in region 2 and 0.48 in region 3
without a leakage correction, and 1.13, 1.10 and 0.66 in the corre-
sponding regions after correction.
4. Discussion
In the present study, accuracy of the out-of-ﬁeld doses calculated by
three TPS algorithms commonly used in clinical practice were com-
pared to measured data acquired in vivo on patients undergoing breast
radiotherapy. The measurement points represented locations of dosi-
metric interest for the purpose of radiation-related risk assessment.
The results showed that accuracy of calculated doses at each mea-
surement point varied amongst the three TPS algorithms. The
discrepancy in calculated doses in comparison to measured doses could
be attributed to varying levels of sophistication of the TPS algorithms.
Overall, the Boltzmann solver data correlated better with in vivo mea-
surements than the convolution-based and pencil beam type algo-
rithms. At measurement points beyond 15 cm from the ﬁeld edge, the
convolution algorithm did not calculate dose. A thorough discussion on
this algorithm is provided by Van Esch et al. [31], who demonstrated
improved accuracy compared to single pencil beam algorithms for in-
ﬁeld locations. The more advanced Boltzmann transport equation
solver was tested by Fogliata et al. [32] in various ﬁeld sizes in the
presence of heterogeneities. It was found to be in close agreement with
Monte Carlo simulations and a marked improvement over convolution-
based methods. Despite varying degrees of sophistication and accuracy
in-ﬁeld, each algorithm in the present work was found to suﬀer in-
accuracies out-of-ﬁeld, and each to varying degrees. This study was not
designed to ascertain the cause of diﬀerences in performance between
algorithms. The Boltzmann solver uses a variable dose calculation grid
size and therefore out-of-ﬁeld dose calculations are averaged over a
larger volume compared with the convolution-based and pencil beam
algorithms. The Boltzmann transport equation solver also models ra-
diation dose distributions in the presence of heterogeneous media with
greater accuracy. A combination of these factors may have contributed
to the improved accuracy at out-of-ﬁeld locations demonstrated in this
study.
Application of a leakage correction improved accuracy of dose
calculations by the Boltzmann solver beyond 19 cm from the ﬁeld edge.
The measured leakage correction of 0.04% is consistent with
International Electrotechnical Commission (IEC) recommendations that
the leakage dose from a medical linear accelerator does not exceed
0.1% of the primary beam at 1m from the source [33]. The leakage
component was likely to be more prominent in distal regions and was
not explicitly modelled by the TPS. However, the correction did not
improve accuracy of calculated doses by the three TPS algorithms at
more proximal measurement points in regions 1 and 2 where the
leakage component was likely to be dominated by head scatter. Out-of-
ﬁeld doses from medical linear accelerators have been shown to vary
with machine design [26,27]. Therefore, leakage corrections would
require experimental veriﬁcation as they are likely to vary depending
on design of the linear accelerators. The single value correction for
leakage dose in the present study did not provide a complete solution
for all measurement regions, as it over-corrected for the discrepancy in
calculated doses by the Boltzmann solver in regions close to the treat-
ment ﬁeld. Nevertheless, an improvement in calculation accuracy was
demonstrated with the added correction for this cohort of patients.
Further work is required to assess the application of this correction to a
wider patient cohort including diﬀerent planning techniques, treatment
sites and linac models. A limitation of this study is that in vivo data is
included from one particular linear accelerator design and calculated
data is a from one TPS vendor. Application of results to a wider patient
population would therefore require further investigation.
The radiation leakage doses, albeit low, are of clinical relevance and
potential signiﬁcance for long term risk-assessment, for example, in a
patient undergoing radiotherapy who is found to be pregnant. The
International Commission on Radiological Protection (ICRP) report 84
[34] states that termination of pregnancy for foetal doses below
100mGy are not recommended, as the risk of foetal complications is
low. For a patient who received a total dose of 50 Gy, the present study
demonstrated that the leakage dose was approximately 20mGy. Al-
though this leakage dose on its own is below the threshold stipulated in
the ICRP guidelines for consideration of termination of pregnancy, in
conjunction with diagnostic imaging and radiation treatment planning
CT scans, the cumulative doses may reach the threshold.
TPS algorithms are not designed nor commissioned to model out-of-
ﬁeld dose. Moreover, the commissioning process can inﬂuence overall
accuracy. The over-estimation of TPS-calculated doses in regions
proximal to the ﬁeld edge may be reduced by modifying the beam
Fig. 3. Comparison of the Boltzmann solver calculations with TLD measured data with
and without application of a leakage dose correction factor of 0.04% of the delivered
dose.
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model in the TPS. However, the present study primarily aimed to im-
prove accuracy of out-of-ﬁeld dose estimates in regions distal from the
ﬁeld edge, which typically corresponded to untargeted healthy tissue.
Thus, accurate quantiﬁcation of radiation doses in these regions is ne-
cessary to improve assessment of the long-term risks associated with
radiotherapy, particularly in patients who are likely to be long-term
survivors including patients with early-stage breast cancer.
The present study showed that the accuracy of radiation dose cal-
culations diminished at peripheral locations where linear accelerator-
speciﬁc leakage and head scatter components were dominant. The ap-
plication of a leakage correction in radiation treatment planning im-
proved TPS dose calculations out-of-ﬁeld. Further investigation into the
application of a leakage dose correction is warranted to improve ac-
curacy of out-of-ﬁeld dose calculations involving critical healthy tissue.
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